MedTrace Logo

Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

NCT07090278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2734

Last updated 2025-07-31

No results posted yet for this study

Summary

This study was conducted to explore the association between ulinastatin treatment and the incidence of sepsis-associated encephalopathy (SAE) in patients with sepsis. The study was divided into two phases: first, a multicenter retrospective observational cohort: to evaluate the correlation between ulinastatin treatment and the risk of SAE; second, a single center prospective observational cohort: to further explore the association between ulinastatin treatment and SAE.

Conditions

  • Sepsis-Associated Encephalopathy

Interventions

DRUG

ulinastatin

Ulinastatin for the treatment of sepsis patients during ICU stay

Sponsors & Collaborators

  • Shusheng Li

    lead OTHER

Principal Investigators

  • Shusheng Li, PhD · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2024-10-31
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07090278 on ClinicalTrials.gov